Y-mAbs Therapeutics

Focus: Y-mAbs Therapeutics is a New York-based oncology-focused biotech specializing in antibody therapies, with a commercial-stage product (DANYELZA/naxitamab) approved for neuroblastoma and breast cancer. The company operates a deep pipeline of 29 programs targeting high-mortality pediatric and adult cancers.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Y-mAbs Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Y-mAbs Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

29 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

DANYELZA

Neuroblastoma, Breast Cancer

Peak

Approved GD2-directed monoclonal antibody at peak commercialization; primary revenue driver and proof-of-concept for Y-mAbs' antibody platform.

Products & Portfolio (1)

Help build intelligence for Y-mAbs Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

124I-Humanized 3F8

Melanoma

N/A

Clinical Trials (1)

NCT02307630PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

N/A

131I-omburtamab

Central Nervous System/Leptomeningeal Neoplasms

N/A

Clinical Trials (1)

NCT05064306131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

N/A

CD38-SADA:177Lu-DOTA Complex

Non-hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT05994157Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

GD2-SADA:177Lu-DOTA Complex

SCLC

Phase 1

Clinical Trials (1)

NCT05130255GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Phase 1

Irinotecan

Neuroblastoma (NB)

Phase 1

Clinical Trials (1)

NCT03189706Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Phase 1

131 I-8H9

Peritoneal Cancer

Phase 1

Clinical Trials (1)

NCT01099644Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Phase 1

Naxitamab

Neuroblastoma

Phase 1

Clinical Trials (1)

NCT07027748Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Phase 1

CD33*CD3 BsAb

AML, Childhood

Phase 1

Clinical Trials (1)

NCT05077423A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

131I-Omburtamab

DIPG

Phase 1

Iodine I 131 MOAB 8H9

Brain and Central Nervous System Tumors

Phase 1

Clinical Trials (1)

NCT00089245Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase 1

Humanized 3F8 Monoclonal Antibody

Neuroblastoma

Phase 1

Clinical Trials (1)

NCT01419834Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Phase 1

Radioactive iodine-labeled monoclonal antibody omburtamab

Brain Cancer

Phase 1

Clinical Trials (1)

NCT01502917Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Phase 1

cyclophosphamide

Neuroblastoma

Phase 1

Clinical Trials (1)

NCT02650648Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Phase 1

radiolabeled DPTA-omburtamab

Leptomeningeal Metastasis

Phase 1/2

Clinical Trials (1)

NCT04315246177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Phase 1/2

adjuvant OPT-821 in a vaccine containing two antigens

Neuroblastoma

Phase 1/2

Clinical Trials (1)

NCT00911560Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Phase 1/2

177Lu-DTPA-omburtamab

Medulloblastoma, Childhood

Phase 1/2

Clinical Trials (1)

NCT04167618177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Phase 1/2

Nivatrotamab

SCLC

Phase 1/2

Clinical Trials (1)

NCT04750239Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Phase 1/2

Hu3F8 With GM-CSF

Neuroblastoma

Phase 1/2

Clinical Trials (1)

NCT01757626Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Phase 1/2

Humanized 3F8 Bispecific Antibody

Neuroblastoma

Phase 1/2

Clinical Trials (1)

NCT03860207Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Phase 1/2

Sacituzumab govitecan

Metastatic Triple-Negative Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT07011654Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2

Irinotecan

Recurrent Medulloblastoma

Phase 2

Clinical Trials (1)

NCT04743661131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2

Hu3F8

Neuroblastoma

Phase 2

Clinical Trials (1)

NCT03033303A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Phase 2

131 I-omburtamab

Desmoplastic Small Round Cell Tumor

Phase 2

Clinical Trials (1)

NCT04022213A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Phase 2

humanized anti-GD2 antibody

Recurrent Osteosarcoma

Phase 2

Naxitamab

Neuroblastoma

Phase 2

Clinical Trials (2)

NCT07537400Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Phase 2

NCT05489887

Naxitamab

Neuroblastoma

Phase 2

Clinical Trials (1)

NCT04909515Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2

Naxitamab and GM-CSF in combination with irinotecan and temozolomide

Neuroblastoma Recurrent

Phase 2

Clinical Trials (1)

NCT04560166Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Phase 2

GM-CSF + Naxitamab

Neuroblastoma

Phase 2

Clinical Trials (1)

NCT03363373Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2

131I-omburtamab

Neuroblastoma

Phase 2/3

Clinical Trials (1)

NCT03275402131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Phase 2/3

Y-mAbs Therapeutics

About Y-mAbs Therapeutics

Why Work Here

Key Products

Products & Portfolio (1)

Watch Out For

Pipeline & Clinical Trials

Open Jobs (0)